NCT04824131 - Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions

HIV Infections

Interventions

DRUG

Oral cabotegravir (CAB)

30 mg tablets

DRUG

CAB LA

Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter

DRUG

Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)

300 mg/200 mg fixed-dose combination tablets

Trial Locations (3)

Ward 21 CRS, Johannesburg

MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala

Spilhaus CRS, Harare